Rhythm Pharmaceuticals, Inc. a biopharmaceutical company headquartered in Boston and traded on Nasdaq under the ticker RYTM, has announced an expanded marketing authorization for its drug, IMCIVREE (setmelanotide), in the United Kingdom. The United Kingdom s Medicines & Healthcare products Regulatory Agency (MHRA) has now sanctioned the use of IMCIVREE for treating obesity and controlling hunger in patients with genetically confirmed Bardet-Biedl syndrome (BBS) or genetically confirmed loss-of-function biallelic pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or biallelic leptin receptor (LEPR) deficiency. This approval extends to adults as well as pediatric patients as young as two years old.
IMCIVREE functions as a melanocortin-4 receptor (MC4R) agonist, addressing certain genetic deficiencies that disrupt the melanocortin pathway in the central nervous system, leading to uncontrolled hunger and obesity in affected patients. This expanded authorization marks a significant milestone, highlighting Rhythm Pharmaceuticals commitment to enhancing the lives of individuals suffering from rare neuroendocrine diseases.
In conjunction with this news, Rhythm Pharmaceuticals has shared compelling results from its Phase 3 VENTURE clinical trial, recently published in the prestigious journal The Lancet Diabetes & Endocrinology . The trial evaluated the efficacy of setmelanotide in young children (ages 2 to under 5) diagnosed with BBS, POMC, PCSK1, or LEPR deficiencies. The findings indicate a positive impact on weight management and hunger control, presenting a hopeful outlook for early-intervention therapies in this vulnerable age group.
In addition to the MHRA authorization and VENTURE trial publication, Rhythm Pharmaceuticals showcased significant findings at ObesityWeek 2024, an annual conference that brings together experts in the field. According to the presentations, real-world data demonstrated a mean Body Mass Index (BMI) decrease of 12.8% in adult patients with acquired hypothalamic obesity after three months of setmelanotide therapy. Patients who continued treatment for six months experienced an even greater mean BMI reduction of 21.3%. Additionally, an extension of the Phase 2 trial reported a 29.7% reduction in fat mass compared to a 7.7% decrease in lean muscle mass over 12 months in a subset of patients.
These results underscore the potential of setmelanotide as a therapeutic option for various forms of genetic and acquired obesity. The data sets the stage for further dialogue and research in optimizing treatment protocols for both rare genetic obesity conditions and acquired hypothalamic obesity.
Rhythm Pharmaceuticals’ continuous effort in expanding IMCIVREE’s reach and gathering robust clinical data has fortified its position as a leader in the fight against obesity driven by genetic and neuroendocrine disorders. As the company navigates regulatory landscapes and capitalizes on promising research findings, it is on a trajectory to deliver life-changing interventions for individuals confronting the challenges of obesity and hunger due to specific genetic causes.
Comments